Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Injection in Advanced Biliary Tract Cancer
NCT05009953Phase 2Terminated
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan liposome injection in biliary tract cancer (BTC), sponsored by CSPC Ouyi Pharmaceutical. Started Sep 2021; status: terminated.
02
Drugs
irinotecan liposome injection
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05009953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009953.